Preliminary Study on Treatment of Crohn's Disease with Infliximab

FU Mingsheng,LIU Hongchun,CHEN Shiyao

DOI: https://doi.org/10.3969/j.issn.1008-7125.2011.01.008

2011-01-01

Abstract:Background:The incidence of Crohn's disease(CD) is increasing in recent years.Infliximab(IFX),an anti-tumor necrosis factor-α antibody,can enhance the healing of mucosal lesions in CD patients.Aims:To investigate the therapeutic effect of IFX on CD.Methods:Sixteen CD inpatients at Shanghai Zhongshan Hospital from July 2008 to June 2009 were enrolled.The severity of CD was evaluated by CDAI score,and the patients were divided into conventional therapy group and IFX group.Patients in the two groups were given mesalazine + prednisone and IFX,respectively.After 8-week treatment,CDAI score,WBC,ESR,CRP and ALB levels were compared between the two groups.Results:Eleven mild active CD patients received conventional therapy,while 5 moderate active CD patients were given IFX.All the patients attained clinical remission,however,2 mild active patients with anal fistula turned to IFX after failure of conventional therapy and remission was then attained.After treatment,CDAI score,ESR and CRP levels were improved in both two groups(P<0.05),however,the lowering of CDAI score in IFX group was significantly higher than that in conventional therapy group(P=0.019).Conclusions:IFX is superior to conventional therapy for inducing clinical remission in CD,and can enhance the healing of anal fistula if conventional therapy fails.